Episode Details

Nano-X Imaging's Q4 2025 was a stark reality check, anchored by a massive $17.5 million impairment charge that highlights the painful gap between medical hardware ambition and actual commercial scale.

In ~10 minutes:

• Why management finally pulled the plug on their South Korean chip fab

• How the Vaso Health IT acquisition bought instant software revenue

• The bureaucratic bottlenecks pushing the hardware ramp to late 2026

• Why the market handed the stock a brutal 24% gap-down 📉

While teleradiology revenues flatlined at $3.1M, the decision to outsource semiconductor manufacturing to Switzerland stops the bleeding from a misguided COVID-era factory build. But with hospital installations still crawling, investors are being asked to endure another painful waiting game to see if the promised deployment momentum arrives.

Nano-X Imaging (NNOX) | Q4 FY2025

AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.